These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36229663)

  • 1. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
    Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Goodall HM; Ranade K; Holland C; Abdullah SE; Sacco JJ; Sato T
    Nat Med; 2022 Nov; 28(11):2364-2373. PubMed ID: 36229663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
    Sacco JJ; Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Holland C; Sato T
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
    N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
    Chen LN; Carvajal RD
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
    Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
    Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
    Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    Carvajal RD; Nathan P; Sacco JJ; Orloff M; Hernandez-Aya LF; Yang J; Luke JJ; Butler MO; Stanhope S; Collins L; McAlpine C; Holland C; Abdullah SE; Sato T
    J Clin Oncol; 2022 Jun; 40(17):1939-1948. PubMed ID: 35254876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tebentafusp for the treatment of metastatic uveal melanoma.
    Schank TE; Hassel JC
    Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
    Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
    Damato BE; Dukes J; Goodall H; Carvajal RD
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.
    Rodrigues M; Ramtohul T; Rampanou A; Sandoval JL; Houy A; Servois V; Mailly-Giacchetti L; Pierron G; Vincent-Salomon A; Cassoux N; Mariani P; Dutriaux C; Pracht M; Ryckewaert T; Kurtz JE; Roman-Roman S; Piperno-Neumann S; Bidard FC; Stern MH; Renault S
    Nat Commun; 2024 Oct; 15(1):8851. PubMed ID: 39402032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
    Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
    Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).
    Luke JJ; Olson DJ; Allred JB; Strand CA; Bao R; Zha Y; Carll T; Labadie BW; Bastos BR; Butler MO; Hogg D; Munster PN; Schwartz GK
    Clin Cancer Res; 2020 Feb; 26(4):804-811. PubMed ID: 31558480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.
    Dian Y; Liu Y; Zeng F; Sun Y; Deng G
    Hum Vaccin Immunother; 2024 Dec; 20(1):2374647. PubMed ID: 39004419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.
    Tomsitz D; Ruf T; Heppt M; Staeger R; Ramelyte E; Dummer R; Garzarolli M; Meier F; Meier E; Richly H; Gromke T; Siveke JT; Franklin C; Klespe KC; Mauch C; Kilian T; Seegräber M; Schilling B; French LE; Berking C; Heinzerling L
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
    Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
    JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.